Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypes
Radiation Oncology Journal
;
: 124-131, 2012.
Article
in English
| WPRIM
| ID: wpr-97536
ABSTRACT
PURPOSE:
To determine whether triple negative (TN) early stage breast cancers have poorer survival rates compared with other molecular types. MATERIALS ANDMETHODS:
Between August 2000 and July 2006, patients diagnosed with stage I, II early stage breast cancers, in whom all three markers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor [HER]-2) were available and treated with modified radical mastectomy or breast conserving surgery followed by radiotherapy, were retrospectively reviewed.RESULTS:
Of 446 patients, 94 (21.1%) were classified as TN, 57 (12.8%) as HER-2 type, and 295 (66.1%) as luminal. TN was more frequently associated with young patients younger than 35 years old (p = 0.002), higher histologic grade (p 0.05).CONCLUSION:
We found that patients with TN early stage breast cancers had no difference in survival rates compared with other molecular subtypes. Prospective study in homogeneous treatment group will need for a prognosis of TN early stage breast cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenobarbital
/
Prognosis
/
Recurrence
/
Breast
/
Breast Neoplasms
/
Mastectomy, Modified Radical
/
Mastectomy, Segmental
/
Receptors, Progesterone
/
Survival Rate
/
Retrospective Studies
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Radiation Oncology Journal
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS